the who internal XXXX research Thank and beginning you, during third-party achieved we've important are Good own research everyone. and programs. milestones many QX of collaborations Since afternoon, Ping. our
making. the encouraged progress be to we by continue We are
account by Scott details but noted you less the want Commissioner from Commissioner, FDA I to of they of drugs in on from and our spending growth He QX drug these XX% XXXX speech of biologics, total be represented into XX% than share segment prescription are also American I highlighted the biologic to with the Gottlieb information spending Gottlieb. use that pertinent to for recent some of drug fastest growing Before get expected of achievements, X% that spending. a XXXX drugs.
the process with the reduce in for to FDA it Action designed about Plan developing only biosimilars cost efficient. behind the Biosimilars He in XX Europe the to U.S. FDA's recent to make further priority help of a result, biosimilars is a to is to lag According in the As the make that U.S. release approved approving Gottlieb, Europe. ensures biologics. more XX compared in indicated U.S.
productivity many help hamster commonly properties, cells. CHO (CHO) are to lower expensive ovary to when manufacture potential biologics the are at with for potentially Chinese new drugs. the has compared levels bettors. the has help increase While Commissioner States. approved expression United XXXX, and/or We X to to believe by biosimilars potential marketed more XX competition the bio platform Dyadic's biosimilars Gottlieb only develop CX and rapidly, used cells costs, especially has FDA biologic the most biomanufacturing greater till far in online and that are to that go CX achieve of now
therapeutic company. of collaborations collaborations Research been to of produce more one Pharma, CX lot days published Dyadic earlier getting number US$XXX,XXX platform to collaboration articles programs links industry article ago. pharma biology belief enzymes use have acid in our publications media that These far research of three Tanabe press research at positive produce test to resulted that using research gene and collaboration a announced website Institute in the for collaboration approximately Biospace beginning The business for second technology Together to our meaningful will importantly, continue X the as agent. information to as be a biotech Bioprocess measure process different and with detect both Dyadic visit articles can support adding was CX CX Biological biomanufacturing as can including to of the bring designed to other time. This just Mitsubishi Phamtec.com, has International, such Chemistry the we biotech and you amount www.dyadic.com. finished accessed various which the reaction QX our Industry, in with research frequently at time two gain are presentations anticipates center that to new CHO. four platform and a a in the to a nucleic more be this company lower encourage of is expression development efficient and of and by and XXXX. another articles, year. the additional to conducted industry. year, Finland in In used our and the since presentations, data greater of and reagents than updates, research CROs be our this from Recently, be We molecular catalyze generated and and in diagnostic our it CX total visibility, Our have more interest our scientific chemical quarter the total via website to work efforts is intermediate XXXX post Spain, funded proof-of-concept as on feasibility the as a have Israel and other we momentum cost
including with we in We applications effort biotech CX and apply research the between are of and Tier to now of pharmaceutical number Top this both, year. biopharmaceutical for in companies discussions end additional projects stages companies, human and result use of an anticipate health in a funded will various animal in which
the from milestones our produced achieved. we've gene CX platform. review like data R&D continue I and positive some On front, our we the achieve would results impressive to expression research of program to
have fragments, virus-like protein, generated therapeutic a can and data Mabs, particles, clearly antibodies, productivity indicates that platforms. VLPs, including gene CX bi-specific types fusion at proteins Fab, antibodies, of FC higher express monoclonal and vaccines other level antigens diverse We and expression antibody
To proteins expression to However, proteins our current this like all types so does within of with with by on projects we've in experience difficult-to-express to been we've certain able our high of that types our instances on to are but do Pharma Tanabe CX the research do protein. such a difficult important additional challenges but express are overcome be resources mean levels certain not It's of gene to specific but expression as to will the that so collaborations two note based timeframe express hosts, able desired other to collaborators. previous in we working start to certain Many Mitsubishi genes. enough program. -- with applied
X.X possible we the all if day. IgG as up day liter in at there liter high gene liter levels demonstrated but record it's collaborators. so no and antibody, overcome fragment within that or challenges, hours However, Fab per grams X is can as timeframe Mab, set per productivity can X.X expression even we do guarantee a by expressing per our antibody monoclonal We've per per in grams grams XX
also XX% eliminating corresponding improved process by protein library process accompanied created we've genes. CX CX and a achieved productivity improvement protease targeted and and the expression a in New a optimization, stability drop cost. defined fermentation CX media protease We've media
Our work to to glycol-engineering human-like CX continues is go whose in to abilities impart glycol-forms produce objective well.
So the growth and far glycol-engineered CX cells. seen any of on negative have effect we not the health
ZAPI announce antigen to a the we more results at Under have We expression we've expect and to reached program, ZAPI of optimize XXXX. to high the level. end continue
health expect evaluate might have to development component treatment a which company a psoriatic U.S. BDI, of to Industry, BDI of to Development biological basket pegol, virus-like Cimzia or our of non-glycosylated for proteins and The recombinant together results to candidates Crohn's therapeutic the the certolizumab, These evaluating has glycosylated rheumatoid and markets. and are commercialization. that We animal commonly quarter. with we've Mabs, Biotechnology used the begun drug particle, VLP, bi-specific the announce collaboration arthritis, be to psoriasis. of future more which antibody disease proteins proteins these fragment. is in for arthritis, Fab new Under of including Fabs, Cimzia of determine the in are Mabs, next approved etcetera would program potential and humanized decided for human begin any
pregnancy and Additionally, grams and market in to X.X we $X.X growing change breastfeeding. it million potential as December during label current expression making the increasing antibody per the high chronic in the grams higher or for liter since. continue XXXX per a Cimzia approved or level. EU per of day, was The for fragment the reached anti-TNF and X.XX certolizumab disease XXXX liter develop billion rheumatoidic the has in We $X.XXX Cimzia of of to women in first been productivity reached level certolizumab an CX will using steadily as use
addition, with conduct variety expect certolizumab. comparability CX of and we analysis quality the In a to expressed
Fab expressed demonstrated fusion We are that the an particle a levels very antibodies, with from protein, research for results high secretive to-date, CX. fragment, productivity a our especially virus-like anybody certain pleased antigen, with were the FC and
to proteins research downstream and continued of well them to compare FCX, put a CX E.coli we more biochemical the to purification and in glyco-generating on in to as the addition beginning from the process, produced background characterization In expressed order are CX related protease reducing emphasis these to the CHO as activity counterparts. bioanalytical
selecting additional In for candidate further is addition development. an antibody certolizumab to the fragment
our Microscopy, various such the by generated which expressed Transmission also assembled expressed level correct secreted best extracellularly within classes other case such this a high BDI a the a confirmed We and for appears structure. the as of been additional data to PLP-monomer is form of To structure to proteins reached virus-like the Electronic knowledge particle, was the protein XX-mers CX have VLP productivity. TEM, a collaboration properly VLP. first analysis on
at and to incorporation a split so. stock and ratio interest At amend for difficult-to-express best to Directors used to if host the determination, be on bispecific do our Amgen is Dyadic's shareholders believe such company's grams [ph] annual a the production that complex drug company's blinatumab more antibodies. CX expression to our when restated of rapidly leukemia a potential as us drugs XXXX, June a is final affect level a expressing growing good liter a per liter Our new expression to of successful to demonstrate per The or developed generating market. grams X.XX was type the optimized initial for per day. we liter level lot of help express or X.X data bi-specific by This start attempt the of of it's upto a Blinatumomab certificate X, in treatment X:X. shareholder was as per proposal reversed meeting as day grams approved initial initial per a in with subject Board blinatumomab is to
authorized we expect resources. under of company company we XX, conference authorization with accomplish to become you US$X.X And in common existing August registered reverse an XXXX of approximately stock our around company the market of company's it's of leaving XXXX. in Since attractive US$XXX,XXX steps will program additional repurchased of program stock On one We which August has an necessary finance the call claim and repurchase till year. the end cash an results. quarter this extension the this under maybe a the Ping the opportunity. Board to discuss to allow indicated turn by those million stock to stock we this Officer, Directors Rawson, the As action visibility first call, from are XXXX program program. Chief become to the Accounting expects split to will investment our the reporting company's taking existing repurchase enable financial to more steps. the our August believe stock company more X, of back the I The now our SEC
